Drug profile · INN
rifamycin sodium
AEMCOLO
rifamycin sodium (AEMCOLO) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rifamycin sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
rifamycin sodium (AEMCOLO) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA-directed RNA polymerase inhibitor
Primary target: DNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rifamycin sodium?
rifamycin sodium (AEMCOLO) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rifamycin sodium?
AEMCOLO is a marketed brand name for rifamycin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rifamycin sodium?
rifamycin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.